Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul 15;27(14):3809-3811.
doi: 10.1158/1078-0432.CCR-21-1376. Epub 2021 May 14.

Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection

Robert S Benjamin  1 , Giorgio Minotti  2
Affiliations
Comment

Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection

Robert S Benjamin et al. Clin Cancer Res. .

Abstract

Doxorubicin cardiac toxicity is widely misunderstood, largely preventable, and starts with the first dose. This article reviews the history of doxorubicin cardiac toxicity and strategies for minimizing it. Dexrazoxane cardioprotection can safely be initiated on day 1 without compromising antitumor activity, allowing doxorubicin administration beyond the reported maximum lifetime dose.See related articles by Van Tine et al., p. 3854 and Jones et al., p. 3861.

PubMed Disclaimer

Comment on

References

    1. Jones RL, Wagner AJ, Kawai A, Tamura K, Shahir A, Van Tine BA, et al. Prospective evaluation of doxorubicin cardiotoxicity in patients with advanced soft-tissue sarcoma treated in the ANNOUNCE phase III randomized trial. Clin Cancer Res. 2021;27:3861–6.
    1. Van Tine BA, Hirbe AC, Oppelt P, Frith A, Rathore R, Mitchell JD, et al. Interim analysis of the Phase II study: non-inferiority study of doxorubicin with upfront dexrazoxane plus olaratumab for advanced or metastatic soft tissue sarcoma. Clin Cancer Res. 2021;27:3854–60.
    1. Lefrak E, Pitha J, Rosenheim S, Gottlieb J. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302–14.
    1. Von Hoff D, Layard M, Basa P, Davis Hvon Hoff A, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7.
    1. Legha S, Benjamin R, Mackay B, Ewer M, Wallace S, Valdivieso M, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133–9.

LinkOut - more resources